Protalix BioTherapeutics (PLX) Profit After Tax (2010 - 2026)

Protalix BioTherapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at $18.3 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 606.13% year-over-year to $18.3 million; the TTM figure through Mar 2026 stood at $15.3 million (up 292.32% YoY), while the FY2025 annual figure was -$6.6 million, down 325.24% from the prior year.
• Profit After Tax was $18.3 million for Q1 2026 at Protalix BioTherapeutics, up from -$5.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $19.3 million in Q2 2023 to a low of -$6.0 million in Q4 2023.
• Historically, Profit After Tax has averaged $472352.9 across 5 years, with a median of -$2.3 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Profit After Tax sank 184.76% in 2025, then soared 606.13% in 2026.
• A 5-year view of Profit After Tax shows it stood at -$3.7 million in 2022, then tumbled by 61.6% to -$6.0 million in 2023, then jumped by 207.45% to $6.5 million in 2024, then tumbled by 184.76% to -$5.5 million in 2025, then jumped by 432.79% to $18.3 million in 2026.
• The last three Profit After Tax figures came in at $18.3 million (Q1 2026), -$5.5 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.